# Positron Emission Tomography/Computed Tomography (PET/CT) Imaging for Radiation Dosimetry, Plasma Pharmacokinetics, Biodistribution, Safety and Tolerability and Diagnostic Performance of BAY86-4367 in Patients With Prostate Cancer and Healthy Volunteers

> **NCT00975299** · PHASE1 · TERMINATED · sponsor: **Bayer** · enrollment: 16 (actual)

## Conditions studied

- Diagnostic Imaging

## Interventions

- **DRUG:** BAY86-4367
- **DRUG:** BAY86-4367

## Key facts

- **NCT ID:** NCT00975299
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-09
- **Primary completion:** 2010-10
- **Final completion:** 2010-10
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2014-06-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00975299

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00975299, "Positron Emission Tomography/Computed Tomography (PET/CT) Imaging for Radiation Dosimetry, Plasma Pharmacokinetics, Biodistribution, Safety and Tolerability and Diagnostic Performance of BAY86-4367 in Patients With Prostate Cancer and Healthy Volunteers". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00975299. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*